Drug Profile
Volagidemab - REMD Biotherapeutics
Alternative Names: AMG-477; REMD-477Latest Information Update: 26 Feb 2024
Price :
$50
*
At a glance
- Originator Amgen
- Developer REMD Biotherapeutics
- Class Antibodies; Antihyperglycaemics
- Mechanism of Action Glucagon receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Type 1 diabetes mellitus; Type 2 diabetes mellitus
- No development reported Glucose intolerance; Metabolic disorders
Most Recent Events
- 15 Feb 2024 REMD Biotherapeutics initiates enrolment in a phase I trial for Type 1 diabetes mellitus (Treatment-experienced) in USA (SC, Injection) (NCT06272695)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Glucose intolerance(Treatment-experienced) in USA (SC, Injection)
- 23 Jun 2023 Updated efficacy data from a phase I/II trial in type 1 diabetes mellitus presented at the 83rd Annual Scientific Sessions of the American Diabetes Association (ADA-2023)